EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Tafasitamab in refractory diffuse large B-cell lymphoma with neurolymphomatosis

João Ricardo Belo Freitas Mendes, Laurine Couleur, Chloe Manca, Valérie Frossard, Mitja Nabergoj

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06184-6 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Hematology, 2025. Verfasst von João Ricardo Belo Freitas Mendes und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hôpital Riviera-Chablais Vaud-Valais, Rennaz, Switzerland. joaoricardobelo4@gmail.com. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Neurolymphomatosis. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peripheral nervous system involvement in lymphoproliferative diseases, often due to direct nerve infiltration (neurolymphomatosis, NL), is mostly seen in aggressive B-cell lymphoma. We report the case of an 88-year-old man with stage IVA DLBCL, who achieved the first complete response after six R-miniCHOP21 cycles. One year post-treatment, he developed severe neurological symptoms, and PET-CT revealed widespread relapse with extensive neural involvement. Treatment with tafasitamab and lenalidomide led to a complete morpho-metabolic remission and full neurological recovery, with minimal side effects. This case underscores for the very first time the efficacy and tolerability of this regimen in treating NL, highlighting its potential for frail patients unfit for more intensive therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseNeurolymphomatosisHumansMaleAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsLenalidomideRituximabVincristine

Stichwörter der Autor:innen

DLBCLLenalidomideNeurolymphomatosisTafasitamab

Substanzen

LenalidomideRituximabVincristine

Autor:innen und Institutionen

  • Department of Internal Medicine, Hôpital Riviera-Chablais Vaud-Valais, Rennaz, Switzerland. joaoricardobelo4@gmail.com.
  • Division of Hematology and Laboratory of Hematology, Institut Central des Hôpitaux, Sion, Switzerland. joaoricardobelo4@gmail.com.
  • Nuclear Medicine, Hôpital Riviera-Chablais Vaud-Valais, Rennaz, Switzerland.
  • Division of Hematology and Laboratory of Hematology, Institut Central des Hôpitaux, Sion, Switzerland.
  • Division of Hematology and Laboratory of Hematology, Institut Central des Hôpitaux, Sion, Switzerland. mitja.nabergoj@hopitalvs.ch.

Zitieren

APA

Mendes, J. R. B. F., Couleur, L., Manca, C., Frossard, V., & Nabergoj, M. (2025). Tafasitamab in refractory diffuse large B-cell lymphoma with neurolymphomatosis. Annals of Hematology. https://doi.org/10.1007/s00277-025-06184-6

Vancouver

Mendes JRBF, Couleur L, Manca C, Frossard V, Nabergoj M. Tafasitamab in refractory diffuse large B-cell lymphoma with neurolymphomatosis. Annals of Hematology. 2025. doi:10.1007/s00277-025-06184-6

BibTeX
@article{Mendes2025,
  author = {Mendes, João Ricardo Belo Freitas and Couleur, Laurine and Manca, Chloe and Frossard, Valérie and Nabergoj, Mitja},
  title = {Tafasitamab in refractory diffuse large B-cell lymphoma with neurolymphomatosis},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06184-6}
}
Kostenlos starten →